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The process of drug development is expensive and time
consuming, with millions of dollars spent on the testing of
new chemical entities [1,2]. Unfortunately many agents that
show initial promising activity against a particular biological
target will be discarded due to concerns regarding their
safety, toxicity and efficacy in humans. There is also a percep-
tion that preclinical models may foster unrealistic expec-
tations, and many promising drugs are failing to reach their
potential. In addition, reporting of clinical trials may disadvan-
tage certain drugs at an early stage in their development.
The introduction of the tyrosine kinase inhibitors was met with
great optimism. Initial agents acted on the erbB signalling
pathways. Activation of these pathways lead to the phos-
phorylation of key downstream signalling elements – such as
mitogen-activated protein kinase, AKT, and insulin-like growth
factor receptor – known to be involved in cancer progression.
Epidermal growth factor receptor (EGFR), a member of the
erbB family, is overexpressed in a wide range of common
solid tumours (nonsmall-cell lung cancer (NSCLC), 40 to
80%; prostate cancer, 40 to 80%; gastric cancer, 33 to 74%;
breast cancer, 14 to 91%; colorectal cancer, 25 to 77%;
pancreatic cancer, 30 to 50%; ovarian cancer, 35 to 70%)
and overexpression is generally associated with poor
prognosis/prognostic factors. Tyrosine kinase inhibitors such
as gefitinib (Iressa™; Astra-Zeneca, London, UK) erlotinib
(Tarceva™; OSI and Roche-Genentech, Basel, Switzerland)
and canertinib (Pfizer, London, UK) block the activation of
intracellular tyrosine kinase sites of EGFR, also called erb B1,
while lapatinib (Tykerb™; GlaxoSmithKline, Middlesex, UK)
blocks the tyrosine kinase sites of EGFR and erb B2 (also
called HER2), decrease signal transduction in vitro and
reduce tumour growth in experimental systems [3].
Phase I clinical trials followed from preclinical experiments,
and these trials produce side effect profiles. For example,
diarrhoea and rash were the most common side effects
encountered with the use of gefitinib. These effects were
shown to be dose dependent, and pharmacodynamic and
pharmacokinetic studies realised regimes acceptable to most
patients [4].
These initial findings led on to phase II clinical trials in
NSCLC with gefitinib as monotherapy in heavily pretreated
patients. The IDEAL 1 and IDEAL 2 trials randomised patients
to gefitinib at a dose of either 250 mg/day or 500 mg/day until
disease progression. These studies demonstrated that the
efficacy was similar at the two doses but that the side effect
profile increased with the 500 mg dose, with a 15%
chemotherapy toxicity criteria grade 3 to 4 toxicity [5-7].
Biomarker studies revealed that gefitinib response required
EGFR expression although the data were conflicting as
regards the level of expression required for response [8].
This encouraging evidence of EGFR-mediated growth sup-
pression led to large multicentre trials in patients with
previously treated NSCLC randomised to chemotherapy in
combination with gefitinib at 250 or 500 mg or with placebo
until disease progression or unacceptable toxicity. Disap-
pointingly there appeared to be no benefit from the addition
of gefitinib at either dose to chemotherapy [9,10]. The
TRIBUTE trial was a multicentre, randomised, double-blind
phase III trial of TARCEVA (erlotinib) plus chemotherapy
versus chemotherapy alone for the first-line treatment of
advanced NSCLC, and also showed no difference in survival.
In breast cancer, activation of the erb family of receptors has
been implicated in the development of endocrine resistance,
particularly tamoxifen resistance in experimental systems.
Additionally, gefitinib may be effective in these tamoxifen-
resistant models [11-13].
There have been several clinical trials of gefitinib in patients
with breast cancer encompassing different stages of the
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disease, such as presurgical disease, and there have been
neoadjuvant studies as well as phase II and then randomised
phase II trials in patients with metastatic disease. Unfortu-
nately the initial results of these studies were often apparently
conflicting, with no consistent picture of efficacy.
Initial trials with gefitinib as monotherapy in postmenopausal
metastatic oestrogen receptor (ER)-positive breast cancer
recruited mainly patients who were heavily pretreated with
chemotherapy, and did not select for EGFR positivity; the
response rates were poor [14,15]. A study combining gefitinib
and herceptin in HER2-positive disease also reported no
benefit [16].
In contrast, a phase II clinical trial carried out by our own
group in treatment-naïve metastatic disease demonstrated a
clear benefit in ER-positive patients (clinical benefit rate,
53%), with the best responses in ER-positive, progesterone
receptor-positive tumours [17]. The study recruited patients
with advanced disease who were ER-positive and had
developed tamoxifen resistance (n = 27) or patients who
were ER-negative and had received no more than one prior
chemotherapy treatment for advanced disease (n = 27). The
study groups were given a loading dose of gefitinib 1,000 mg
on day 1 and then 500 mg/day until disease progression or
unacceptable toxicity. The gefitinib responders all expressed
EGFR and demonstrated parallel decreases in tumour
phosphorylated EGFR, phosphorylated mitogen-activated
protein kinase and Ki67 with treatment.
Presurgical studies with gefitinib are difficult to interpret. In a
small study, patients with dual EGFR-positive, ER-positive
primary breast cancers were randomised to gefitinib with or
without aromatase inhibitor anastrazole [18]. The combination
regime led to a greater decrease in Ki67 levels and a better
tumour response than gefitinib alone. A further presurgical
study confirmed the requirement for EGFR expression in the
tumour, and suggested that EGFR inhibition may be more
effective in ER-positive, progesterone receptor-negative
breast cancers [19]. In a randomised neoadjuvant trial of
gefitinib and anastrazole versus anastrazole alone in ER-
positive, EGFR-negative tumours there was no significant
difference in Ki67 levels at 2 or 16 weeks for either combi-
nation and there were no statistically significant differences in
response rates between the groups [20].
There are also two randomised phase II studies with gefitinib
in breast cancer patients. The first study compared gefitinib
with or without tamoxifen in ER-positive patients (either endo-
crine naïve or previously treated with adjuvant tamoxifen
(stratum 1) or with adjuvant/metastatic anastrozole (stratum
2)). There was an apparent separation of the progression-free
survival curves for the first group, indicating that gefitinib may
have a role in preventing or delaying the development of
endocrine resistance [21]. The second randomised phase II
study in ER-positive, treatment-naïve, metastatic breast cancer
randomised between anastrazole versus anastrazole and
geftinib – the study reported a median progression-free
survival of 14 months for the combination regimen versus
8 months for anastrozole alone [22]. Interestingly the clinical
benefit rate in this study was 48% for the combination versus
34% for anastrozole alone; however, the objective response
rate was better for anastrazole alone (12%) compared with
the combination regime (2%). It is difficult to suggest a
rationale where a drug improves clinical benefit rate but
shows an apparent opposite effect on objective response
Interestingly, there is evidence to suggest that gefitinib is
more effective in certain populations – that is, nonsmokers
compared with smokers, Asian compared with Caucasian,
and women compared with men [23]. Additionally, two
publications report that somatic mutations in the tyrosine
kinase domain of the EGFR appear to increase the sensitivity
of the mutant receptor to gefitinib [24,25]. A recent paper
has also reported that gefitinib alone is significantly more
effective than standard chemotherapy in mutation-positive
tumours but the reverse is true in mutation-negative lung
cancers [26]. These findings highlight the importance of
identifying the appropriate population to treat with
appropriate predictive biological marker(s)
In summary, trials in metastatic breast cancer have shown no
efficacy in heavily pretreated patients. Efficacy has been seen
in some clinical studies in Tam-R tumours expressing EGFR,
but the level of EGFR expression was not predictive. Rando-
mised phase II clinical trials have failed to demonstrate
significant effects when gefitinib was added to tamoxifen, but
retrospective analysis has suggested that gefitinib may have
been more effect in a hormone-naive subgroup. A small
randomised phase II study of anastrozole with or without
gefitinib, however, has reported a significant benefit in favour
of the combination.
Presurgical and neoadjuvant studies do not provide a
consistent picture of what type of tumours were sensitive to
gefitinib or what tissue markers reflect or predict biological
effects. Clinical studies do not correlate well with biological
studies except that, in general, EGFR expression is required
to see any biological activity.
More recently, lapatinib – a tyrosine kinase inhibitor that
targets not only EGFR (erb B1) but also erb B2 (HER2)
receptor tyrosine kinase signalling – has been studied.
Following promising preclinical results [27], a phase III
randomised, double-blind trial of lapatinib and placebo versus
lapatinib and letrozole in ER-positive, treatment-naïve
metastatic breast cancer (n = 1,286) has shown a benefit in
clinical benefit rate and progression-free survival in the HER2-
positive subpopulation. There was no significant effect from
the addition of lapatinib in the much larger HER2-negative
subpopulation, suggesting that lapatinib acts at least in large
part through the inhibition of the tyrosine kinase on the HER2.The current spectrum of preclinical models only partially
reflects the true heterogeneity of breast cancer, and as
clinicians we must be aware of the limitations of results from
these model systems. Clinical trials are still essential to the
development of new generations of biological agents but
traditional large clinical trials may not be the best way of
evaluating agents that have a target expressed in only a
minority of breast cancers. We must strive to have a better
understanding of tumour biology. This involves identifying not
only a therapy and the target it might hit, but also the
biological markers that predict and measure efficacy (or not)
of treatment. This needs to be highlighted not simply in large
randomised trials that compare very heterogeneous tumour
types, but in individual cancers or at least small groups of
tumours that can be characterised biologically.
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